| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, the company's current Chief Executive Officer, has resumed his position as Chief Executive Officer and President, a position he held from September 2004 through September 2006.
The company also announced that James A. Merritt's employment relationship with the company ended, effective January 29, 2008. Dr. Merritt previously served as the company's President and Chief Medical Officer. In connection with these events, the underlying responsibilities of the Chief Medical Officer and President positions have been consolidated. Joachim P.H. Schupp, M.D., who has served as the company's Vice President, Medical Affairs since August 2006, will lead the company's clinical group and assume Dr. Merritt's clinical responsibilities, and Mr. Levine will resume the corporate responsibilities of the President.
"We have an experienced team that will continue to rapidly advance our lead programs and we are excited by our continued progress and anticipate achieving additional milestones in 2008," stated Mr. Levine. "On behalf of our board of directors and the entire management team, we thank Jay for his contributions to the company and wish him well," added Mr. Levine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals seeks to improve the performance and safety of
existing treatments by addressing significant problems such as drug
metabolism, bioavailability, excessive toxicity and treatment resistance.
More information can be found on the
'/>"/>
| SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |